Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.

Marine Malbec (1, 2) , Françoise Porrot (1) , Rejane Rua (1, 2) , Joshua Horwitz (3) , Florian Klein (3) , Ari Halper-Stromberg (3) , Johannes F Scheid (3) , Caroline Eden (3) , Hugo Mouquet (4) , Michel C Nussenzweig (3, 5) , Olivier Schwartz (1)

1 Virus et Immunité
2 Cellule Pasteur UPMC
3 Laboratory of Molecular Immunology
4 Réponse humorale aux pathogènes
5 HHMI - Howard Hughes Medical Institute

The neutralizing activity of anti-HIV-1 antibodies is typically measured in assays where cell-free virions enter reporter cell lines. However, HIV-1 cell to cell transmission is a major mechanism of viral spread, and the effect of the recently described broadly neutralizing antibodies (bNAbs) on this mode of transmission remains unknown. Here we identify a subset of bNAbs that inhibit both cell-free and cell-mediated infection in primary CD4(+) lymphocytes. These antibodies target either the CD4-binding site (NIH45-46 and 3BNC60) or the glycan/V3 loop (10-1074 and PGT121) on HIV-1 gp120 and act at low concentrations by inhibiting multiple steps of viral cell to cell transmission. These antibodies accumulate at virological synapses and impair the clustering and fusion of infected and target cells and the transfer of viral material to uninfected T cells. In addition, they block viral cell to cell transmission to plasmacytoid DCs and thereby interfere with type-I IFN production. Thus, only a subset of bNAbs can efficiently prevent HIV-1 cell to cell transmission, and this property should be considered an important characteristic defining antibody potency for therapeutic or prophylactic antiviral strategies.

Domains: Immunology; Virology

Marine Malbec, Françoise Porrot, Rejane Rua, Joshua Horwitz, Florian Klein, et al.. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.. Journal of Experimental Medicine, 2013, 210 (13), pp.2813-21. ⟨10.1084/jem.20131244⟩. ⟨pasteur-01108608⟩